Stockreport

Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo [Yahoo! Finance]

Nuvation Bio Inc. Class A  (NUVB) 
PDF Agreement provides Nuvation Bio ownership of global clinical development program, inclusive of clinical trials, past and current data generation, and future publication [Read more]